Why screen when you can create? Novel and selective lead structures in weeks from Enki™
Trained on more than 570 targets across more than 10 target classes, with more being added regularly.
No data required. Just define your TPP and Enki does the rest. Enki is a single generative algorithm trained on decades worth of experimental data with proven results.
Define your TPP
Select your on-target(s), off-target(s), and other properties in minutes.
570+ targets
(GPCRs, kinases, hydrolases, proteases, NHRs, integrins, and more)
{{item}}
The Enki™ Platform is the first commercially accessible foundation model for small molecules.
Company
Founded in September 2019, we are a team of experienced AI/machine learning researchers and medicinal and computational chemists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to redefine the unit economics of drug discovery and development.
Our Team
We are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
Handol Kim
Ahmad Issa,
PhD
Jason Rolfe,
PhD
Marshall Drew-Brook
Ali Saberali,
PhD
Peter Guzzo,
PhD
Roslynn Drewitt-Lange
Sara Ibrahim Omar,
PhD
Nathania Takyi,
MSc
Sree Vadlamudi,
PhD
Board and Advisors
Frank Chang
Board Member
Jennifer Hamilton
PhD, Advisor (Strategy/Commercial)
Todd Farrell
Advisor (Strategy)
Nancy Harrison
Advisor (Strategy/ Commercial)
Scientific Advisory Board
Robert N. Young
PhD, SAB Member (Medicinal Chemistry)
John Boylan
PhD, SAB Member (Cell Biology/Oncology drug discovery)
Alexander Tropsha
PhD, SAB Member (Cheminformatics)
Artem Cherkasov
PhD, SAB Member (Cheminformatics)
Funding, Partners & Investors
Founded in September 2019, we are a team of experienced AI/machine learning and business specialists applying state of the art generative AI to drug discovery in close collaboration with biopharmaceutical partners to bring new therapeutics to market across disease areas and positively impact lives.
In the Press
Cutting through the noise of machine learning for drug discovery
Generative Machine Learning Can Construct Smooth Chemical Search Spaces for Efficient Drug Discovery
Funding news: AI-fueled drug discovery startup and auto safety company raise cash
Handol Kim of Variational AI On The Future Of Artificial Intelligence
Recent News & Events
Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BC
Read more: Variational AI Named “Emerging Company of the Year – Biotech” by Life Sciences BCVariational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic Dermatitis
Read more: Variational AI and Oncocross to Collaborate on AI-Driven Drug Discovery Program in Atopic DermatitisVariational AI announces a co-development agreement with Oncocross, to co-develop a novel small molecule inhibitor for chronic skin inflammation focusing on atopic dermatitis.
Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™
Read more: Accelerating the Discovery of Brain-Penetrant ATR Inhibitors with Enki™Variational AI partnered with Rakovina Therapeutics to support the discovery of a brain-penetrant ATR inhibitor using our Enki™ generative AI platform. By generating and prioritizing novel, CNS-targeting compounds aligned with…
View All News & Updates
Variational AI is hiring!
Please see open job listing below or contact us if you would like to join the team in the area of machine learning, computational medicinal chemistry, and business development.